Home > Riviste > Minerva Chirurgica > Fascicoli precedenti > Minerva Chirurgica 2015 October;70(5) > Minerva Chirurgica 2015 October;70(5):319-25

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi PROMO
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Estratti
Per citare questo articolo

 

ORIGINAL ARTICLES   Freefree

Minerva Chirurgica 2015 October;70(5):319-25

Copyright © 2015 EDIZIONI MINERVA MEDICA

lingua: Inglese

Topical application of LEVORAG® as first-line treatment for chronic anal fissures: a preliminary multicentric study

Giordano P. 1, Mistrangelo M. 2, Cracco N. 3, D’Elia A. 4, Creperio G. 5, Digito F. 6, Paduano R. 5, Tapparo A. 7, Quinto S. 8, Villa E. 9, Pagano C. 10

1 Barts Health NHS Trust, London, UK; 2 Digestive and Colorectal Surgical Department, Centre of Minimal Invasive Surgery, University of Turin Città della Salute e della Scienza Hospital Turin, Italy; 3 Department of Surgery, Sacro Cuore Don Calabria di Negrar Hospital, Verona, Italy; 4 Department of Surgery, Civil Hospital, Legnano, Milan, Italy; 5 Department of Surgery, Menaggio Hospital, Como, Italy; 6 Department of Surgery, San Daniele Hospital, San Daniele del Friuli, Udine, Italy; 7 Department of Surgery, Maria Pia Hospital, Kronosan Group, Turin, Italy; 8 Department of Surgery, Civil Hospital, Tione di Trento, Trento, Italy; 9 Department of Surgery, Civil Hospital, Mirandola, Modena, Italy; 10 Department of Surgery, Circolo di Melegnano Hospital, Melegnano, Milan, Italy


PDF


AIM: The aim of the present study was to assess the safety and efficacy of this new topical agent as a first line treatment in patients with chronic anal fissures.
METHODS: Nine centres were involved in the study. Patients with chronic anal fissures were recruited and received Levorag® for 40 days. Follow-up visits were conducted at 10, 20 and 40 days from the recruitment. Primary outcome was the healing rate, secondary outcome the reduction of pain at the end of the treatment measured with a VAS scale.
RESULTS: Fifty patients completed the treatment. No adverse events were recorded. 60% of patients healed completely at the end of the treatment. In those that did not heal the reduction of mean VAS values was 60%.
CONCLUSION: The use of Levorag® on patients affected by chronic anal fissures achieved in the short term results similar to those experienced by more classic local treatments without any side effect.

inizio pagina